Romosozumab per migliorare la densità minerale e l'architettura ossea nella SCI cronica (Chronic Romo)
Treatment for sublesional bone loss (osteoporosis) in persons with chronic, motor-complete spinal cord injury (SCI) has been limited and unsuccessful to date. Romosozumab, a sclerostin antagonist, has potential to increase bone formation (anabolic) and decrease bone resorption (anti-catabolic) in persons with chronic SCI. Conventional anti-resorptive therapy alone would not be anticipated to reverse sublesional bone loss in a timely manner because the skeleton below the level of lesion in chronic SCI is assumed to be in a low turnover state. However, because there is a high likelihood that the bone accrued while on romosozumab will be lost once discontinued, denosumab, an anti-resorptive agent, will be administered after treatment with romosozumab, to maintain or, possibly, to continue to increase, bone mineral density (BMD).
The purpose of this study is to address the gap in the treatment of osteoporosis in individuals with chronic SCI by partially restoring BMD with romosozumab treatment for 12 months and then to maintain, or further increase, BMD with denosumab treatment for 12 months. A two group, randomized, double-blind, placebo-controlled clinical trial will be conducted in 39 participants who have chronic (>3 years), motor-complete or incomplete SCI and areal BMD (aBMD) values at the distal femur of at the distal femur <1.0 g/cm2 measured by dual photon X-ray absorptiometry (DXA). The intervention group will receive 12 months of romosozumab followed by 12 months of denosumab, and the control group will receive 12 months of placebo followed by 12 months denosumab.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
Persons with chronic spinal cord injury (SCI) have markedly reduced bone mass and the loss of skeletal architectural integrity, which predisposes them to low-impact fractures. Currently, there is no practical treatment to reverse the severe bone loss in persons with chronic SCI. In the proposed study, a dual pharmacological intervention will be tested to improve bone health. Restoration of bone mass below the level of injury would be expected to reduce the morbidity associated with fractures and permit safer participation in upright activities. Quality of life would be substantially improved because of the ability to engage more securely in activities of daily living and to integrate into the community. Despite the depressed skeletal activity below the level of lesion in persons with chronic SCI, net bone loss occurs because resorption exceeds formation, with a difference between these rates in those with SCI being greater than that observed in the able-bodied population. Thus, it would be anticipated to be of value in persons with chronic SCI to increase bone turnover with the objective to increase bone formation over that of bone resorption. In a preclinical study that administered an anti-sclerostin antibody to rats 12 weeks after complete spinal cord transection bone, mineral density (BMD) was almost fully restored at the distal femoral metaphysis, with improved bone structure, and mechanical strength; in contrast, vehicle-treated animals after complete spinal transection had a marked reduction in distal femoral metaphysis BMD and a deterioration in bone structure and mechanical strength. When used to treat postmenopausal osteoporosis, romosozumab, a human monoclonal anti-sclerostin antibody, was more effective to increase bone mineral density (BMD) and to reduce fracture than any other anti-resorptive or bone-anabolic agent, and this effect was also evident for the appendicular skeleton, which is the site in individuals with chronic SCI of greatest bone loss and most frequent fracture. Because of the absence of clinical options available for the treatment of osteoporosis in individuals with chronic paralysis, the investigators have proposed to test an antagonist of sclerostin, which is a potent bone anabolic agent with proven efficacy in treating women with postmenopausal osteoporosis, to improve bone mass and reduce fragility fractures.
Thirty-nine male and female subjects with chronic, motor-complete or incomplete SCI (>3 years post injury, American Spinal Injury Association Impairment Scale A & B) between the ages of 18 and 55 years old (for females) or 65 years old (for males) who have aBMD at the distal femur at the distal femur <1.0 g/cm2 will be recruited for participation in a randomized, double-blind, placebo-controlled, parallel group clinical trial. The outcome measures of the proposed study are bone mineral density (BMD) by peripheral quantitative computed tomography (pQCT) and dual energy x-ray absorptiometry (DXA), and biochemical markers of bone resorption and formation. This prospective, randomized, placebo controlled clinical trial will take place at the James J. Peters VA Medical Center (JJPVAMC) and Kessler Institute for Rehabilitation (KIR) (each facility will perform patient enrollment and study procedures).
Tipo di studio
Tipo di studio
Iscrizione (Effettivo)
Iscrizione
Fase
Fase
- Fase 2
Contatti e Sedi
Luoghi di studio
-
-
New Jersey
-
West Orange, New Jersey, Stati Uniti, 07052
- Kessler Institute for Rehabilitation
-
-
New York
-
The Bronx, New York, Stati Uniti, 10468-3904
- James J. Peters VA Medical Center, Bronx, NY
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Motor-complete or incomplete spinal cord injury (SCI) [all levels of lesion] classified using International Standards for Neurological Classification for Spinal Cord Injury (ISNCSCI) impairment scale] as ISNCSCI score A-C
- Duration of injury >3 years
- Males (18-65 years old) and females (premenopausal, between the ages of 18 and 55 years old).
- Areal bone mineral density (aBMD) at the distal femur <1.0 g/cm2 (determined at screening)
Exclusion Criteria:
- Long-bone fracture of the leg within the past year
- History of prior bone disease (Paget's hyperparathyroidism, etc.)
- Active and/or history of coronary heart disease or stroke within the past year
- Postmenopausal women
- Men with known hypogonadism prior to spinal cord injury (SCI)
- Anabolic therapy longer than six months duration after spinal cord injury (SCI)
- Glucocorticoid administration longer than three months duration within the last year, and/or prescribed moderate or high dose corticosteroids (>40 mg/d prednisone or an equivalent dose of other corticosteroid medication) for longer than one week, not including drug administered to preserve neurological function at the time of acute spinal cord injury (SCI)
- Endocrinopathies (hyperthyroidism, Cushing's disease or syndrome, etc.)
- Severe underlying chronic disease (e.g., COPD, end-stage heart disease, chronic renal failure)
- Heterotopic ossification (HO) of the knee region (the distal femoral epiphysis is the primary endpoint); HO to any other boney region will not prevent study participation as long as contraindicated medications have not been prescribed)
- Chronic alcohol abuse
- Hypocalcemia
- Pregnancy
- Prescribed a bisphosphonate for HO, or prescribed any other agent to treat osteoporosis other than calcium and vitamin D
- Electrical stimulation of the lower extremities
- Current diagnosis of cancer or history of cancer
- Osteosarcoma
- Life expectancy less than 5 years
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Prevenzione
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Triplicare
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: Romosozumab Treatment (baseline to month 11)
Of the thirty-nine (39) individuals with chronic spinal cord injury (SCI) enrolled in this study, twenty-six (26) participants will be randomly selected to received romosozumab (210mg SQ) once a month for 12 months. |
39 subjects with chronic SCI will be studied with a 2:1 ratio of randomization of drug to placebo. Romosozumab (210mg SQ) will be administered once a month for 12 months. Participants will arrive at the JJPVAMC or KIR once a month to receive injections of romosozumab or placebo. A designated unblinded healthcare professional will be responsible for administering these injections.
Altri nomi:
|
|
Comparatore placebo: Placebo (baseline to month 12)
Of the thirty-nine (39) individuals with chronic SCI enrolled in this study, thirteen (13) participants will be randomly selected to received placebo injections (NS SQ) once a month for 12 months. They will follow study procedures identical to those performed by individuals in the treatment (romosozumab) group. |
Thirteen (13) of the thirty-nine (39) subjects enrolled in this study will be randomly selected to receive placebo (NS SQ) injections for 12 months (baseline - month 11). The placebo injections will be administered by an unblinded healthcare professional (registered nurse / physician). Participants will be blinded to their group assignment (romosozumab treatment or placebo).
Altri nomi:
|
|
Comparatore attivo: Denosumab (month 12 to month 24)
Both groups (treatment and placebo) will receive denosumab (60mg SQ) at months 12 and 18 for maintenance of or to further increase bone mineral density (BMD) at regions of interest (ROI). |
Because there is a high likelihood that the bone accrued while on romosozumab will be lost once discontinued, denosumab, an anti-resorptive agent, will be administered after treatment with romosozumab, to maintain or, possibly, to continue to increase, bone mineral density. Denosumab will be administered to both groups (treatment and placebo) for an additional 12 months. Participants will be asked to arrive at the JJPVAMC once every 6 months to receive injections of denosumab by a healthcare professional.
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change in vBMD at the Distal Femur, measured by pQCT after 12 months of romosozumab treatment
Lasso di tempo: Baseline (0), Month 6, Month 12
|
Percent change of volumetric BMD (vBMD) milligrams per cubic centimeter (mg/cm^3)at the distal femur, measured by peripheral quantitative computed tomography (pQCT) (slice thickness 2.4mm, default voxel size of 0.5mm), with 12 months of romosozumab therapy. vBMD measurements will be taken at baseline, month 6 and month 12. |
Baseline (0), Month 6, Month 12
|
|
Change in vBMD at the distal femur after an additional 12 months of denosumab treatment
Lasso di tempo: Month 18, Month 24
|
Percent change of Integral vBMD (mg/cm^3)at the distal femur, measured by pQCT (slice thickness 2.4mm, default voxel size of 0.5mm), after additional 12 months of denosumab therapy. vBMD measurements will be taken by pQCT at months 18 and 24. |
Month 18, Month 24
|
Altre misure di risultato
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Additional variables by pQCT - vBMD Proximal Tibia
Lasso di tempo: Baseline (0), Month 6, Month 12, Month 18, Month 24
|
Percent change in proximal tibia vBMD (mg/cm^3), measured by pQCT (slice thickness 2.4mm, default voxel size of 0.5mm) at baseline, month 6, month 12, month 18, and month 24. |
Baseline (0), Month 6, Month 12, Month 18, Month 24
|
|
Additional variables by pQCT - tBMD Distal Femur
Lasso di tempo: Baseline (0), Month 6, Month 12, Month 18, Month 24
|
Percent change in distal femur trabecular BMD (tBMD) (mg/cm^3) will be measured by pQCT (slice thickness 2.4mm, default voxel size of 0.5mm) at baseline, month 6, month 12, month 18, and month 24. |
Baseline (0), Month 6, Month 12, Month 18, Month 24
|
|
Additional variables by pQCT - tBMD Proximal Tibia
Lasso di tempo: Baseline (0), Month 6, Month 12, Month 18, Month 24
|
Percent change in proximal tibia tBMD (mg/cm^3) will be measured by pQCT (slice thickness 2.4mm, default voxel size of 0.5mm) at baseline, month 6, month 12, month 18, and month 24. |
Baseline (0), Month 6, Month 12, Month 18, Month 24
|
|
Additional variables by pQCT - cortical BMD of the tibia (38% of the tibial length)
Lasso di tempo: Baseline (0), Month 6, Month 12, Month 18, Month 24
|
Percent change in cortical vBMD (mg/cm^3) will be measured by pQCT (slice thickness 2.4mm, default voxel size of 0.5mm) at baseline, month 6, month 12, month 18, and month 24. |
Baseline (0), Month 6, Month 12, Month 18, Month 24
|
|
Additional variables by pQCT - Distal Tibia Microarchitecture
Lasso di tempo: Baseline (0), Month 6, Month 12, Month 18, Month 24
|
Through the use of a custom software package (pQCT OsteoQ, Inglis Software Solutions Inc., Hamilton, ON) combined threshold-based and region-growing algorithms will be used to measure trabecular microarchitecture [trabecular separation (Tb.Sp), bone volume fraction (BV/TV), trabecular number (Tb.N), and trabecular thickness (Tb.Th)] at baseline, month 6, month 12, month 18, and month 24. |
Baseline (0), Month 6, Month 12, Month 18, Month 24
|
|
Additional variables by DXA - aBMD Distal Femur and Proximal Tibia (i.e. knee)
Lasso di tempo: Baseline (0), Month 6, Month 12, Month 18, Month 24
|
Percent change of regional BMD of the knee (e.g., distal femoral and proximal tibial epiphyses using the orthopedic knee software commercially available from GE Lunar). The starting point to acquire the knee is set on the tibia approximately 10 cm distal from the edge of the patella, with the scan field extending to the epiphysis and metaphysis of the distal femur. aBMD measurements will be taken at Baseline (0), Month 6, Month 12, Month 18, Month 24. |
Baseline (0), Month 6, Month 12, Month 18, Month 24
|
|
Additional variables by DXA - aBMD Hip
Lasso di tempo: Baseline (0), Month 6, Month 12, Month 18, Month 24
|
Percent change in aBMD of the hips (total dual dip and subregions) will be measured at Baseline (0), Month 6, Month 12, Month 18, Month 24. Accepted values for T-score and Z-scores of the hip will be utilized. |
Baseline (0), Month 6, Month 12, Month 18, Month 24
|
|
Biomarkers for Bone Resorption (CTx)
Lasso di tempo: Baseline (0), Month 1, Month 3, Month 6, Month 12, Month 18, Month 24
|
Change in levels of the circulating biochemical markers of bone resorption and formation before (baseline) and after initiating romosozumab therapy (1, 3, 6, and 12 months), and then after 6 and 12 months of denosumab administration will be measured. Levels of serum C-telopeptide (CTx) (ABclonal. 86 Cummings Park, Woburn, MA) will be measured as the biomarker of bone resorption. |
Baseline (0), Month 1, Month 3, Month 6, Month 12, Month 18, Month 24
|
|
Biomarkers for Bone Formation (osteocalcin, alkaline phosphatase, P1NP)
Lasso di tempo: Baseline (0), Month 1, Month 3, Month 6, Month 12, Month 18, Month 24
|
Change in levels of the circulating biochemical markers of bone resorption and formation before (baseline) and after initiating romosozumab therapy (1, 3, 6, and 12 months), and then after 6 and 12 months of denosumab administration will be measured. Serum osteocalcin (Alpco Diagnostics, Salem, NH), bone alkaline phosphatase (MyBiosource, Inc., San Diego, CA) and propeptide of type 1 procollagen (P1NP) (MyBiosource, Inc., San Diego, CA) will be measured as biomarkers of bone formation. |
Baseline (0), Month 1, Month 3, Month 6, Month 12, Month 18, Month 24
|
|
Calcium Metabolism Studies
Lasso di tempo: Baseline (0), Month 1, Month 3, Month 6, Month 12, Month 18, Month 24
|
Serum total and ionized calcium concentration, 24-hour urine calcium, 25 OH-vitamin D level (DiaSorin Inc. Stillwater, MN), 1,25 (OH)2-vitamin D level (Quest Diagnostics), and intact PTH level (ALPCO Diagnostics, Salem, NH) will be measured.The serum 25 OH-vitamin D level will be measured at baseline and 12 and 24 months; more frequent measurement will be performed, if indicated. Serum total and ionized calcium concentrations will be measured at baseline, 1, 3 months, and at 6-month intervals until month 24. |
Baseline (0), Month 1, Month 3, Month 6, Month 12, Month 18, Month 24
|
|
General Endocrine Studies
Lasso di tempo: Baseline (0), Month 12, Month 24
|
Serum thyroid function (T3, T4, & TSH; DiaSorin Inc. Stillwater, MN) will be determined by kit assay. |
Baseline (0), Month 12, Month 24
|
|
Additional variables by pQCT - Distal Tibia Microarchitecture
Lasso di tempo: Baseline (0), Month 6, Month 12, Month 18, Month 24
|
Through the use of a custom software package (pQCT OsteoQ, Inglis Software Solutions Inc., Hamilton, ON) combined threshold-based and region-growing algorithms will be used to bone volume fraction (BV/TV)at baseline, month 6, month 12, month 18, and month 24. |
Baseline (0), Month 6, Month 12, Month 18, Month 24
|
|
Additional variables by pQCT - Distal Tibia Microarchitecture
Lasso di tempo: Baseline (0), Month 6, Month 12, Month 18, Month 24
|
Through the use of a custom software package (pQCT OsteoQ, Inglis Software Solutions Inc., Hamilton, ON) combined threshold-based and region-growing algorithms will be used to measure trabecular number (Tb.N) at baseline, month 6, month 12, month 18, and month 24. |
Baseline (0), Month 6, Month 12, Month 18, Month 24
|
|
Additional variables by pQCT - Distal Tibia Microarchitecture
Lasso di tempo: Baseline (0), Month 6, Month 12, Month 18, Month 24
|
Through the use of a custom software package (pQCT OsteoQ, Inglis Software Solutions Inc., Hamilton, ON) combined threshold-based and region-growing algorithms will be used to measure trabecular thickness (Tb.Th)at baseline, month 6, month 12, month 18, and month 24. |
Baseline (0), Month 6, Month 12, Month 18, Month 24
|
|
Calcium Metabolism Studies
Lasso di tempo: Baseline (0), Month 1, Month 3, Month 6, Month 12, Month 18, Month 24
|
Serum ionized calcium concentration will be measured at baseline, months 1, 3, 6, 12, 18, and 24. |
Baseline (0), Month 1, Month 3, Month 6, Month 12, Month 18, Month 24
|
|
Calcium Metabolism Studies
Lasso di tempo: Baseline (0), Month 1, Month 3, Month 6, Month 12, Month 18, Month 24
|
24-hour urine calcium will be measured at baseline, months 1, 3, 6, 12, 18, and 24. |
Baseline (0), Month 1, Month 3, Month 6, Month 12, Month 18, Month 24
|
|
Calcium Metabolism Studies
Lasso di tempo: Baseline (0), Month 1, Month 3, Month 6, Month 12, Month 18, Month 24
|
25 OH-vitamin D levels (DiaSorin Inc. Stillwater, MN) will be measured at baseline and 12 and 24 months; more frequent measurement will be performed, if indicated. |
Baseline (0), Month 1, Month 3, Month 6, Month 12, Month 18, Month 24
|
|
Calcium Metabolism Studies
Lasso di tempo: Baseline (0), Month 1, Month 3, Month 6, Month 12, Month 18, Month 24
|
1,25 (OH)2-vitamin D level (Quest Diagnostics), will be measured at baseline and 12 and 24 months; more frequent measurement will be performed, if indicated. |
Baseline (0), Month 1, Month 3, Month 6, Month 12, Month 18, Month 24
|
|
Calcium Metabolism Studies
Lasso di tempo: Baseline (0), Month 1, Month 3, Month 6, Month 12, Month 18, Month 24
|
Intact PTH level (ALPCO Diagnostics, Salem, NH) will be measured at Baseline (0), Month 1, Month 3, Month 6, Month 12, Month 18, Month 24 |
Baseline (0), Month 1, Month 3, Month 6, Month 12, Month 18, Month 24
|
|
General Endocrine Studies
Lasso di tempo: Baseline (0), Month 12, Month 24
|
Serum cortisol will be measured by kit assay (MP Biomedicals, Orangeburg, NY). |
Baseline (0), Month 12, Month 24
|
|
General Endocrine Studies
Lasso di tempo: Baseline (0), Month 12, Month 24
|
Serum total testosterone (T) will be determined by kit assay (MP Biomedicals, Orangeburg, NY). |
Baseline (0), Month 12, Month 24
|
|
General Endocrine Studies
Lasso di tempo: Baseline (0), Month 12, Month 24
|
Serum free testosterone (calculated from total T, albumin and SHBG) will be measured by kit assay (MP Biomedicals, Orangeburg, NY). |
Baseline (0), Month 12, Month 24
|
|
General Endocrine Studies
Lasso di tempo: Baseline (0), Month 12, Month 24
|
Serum estradiol (E2) will be measured by kit assay (MP Biomedicals, Orangeburg, NY). |
Baseline (0), Month 12, Month 24
|
|
General Endocrine Studies
Lasso di tempo: Baseline (0), Month 12, Month 24
|
Serum growth hormone (GH) will be measured by kit assay (MP Biomedicals, Orangeburg, NY). |
Baseline (0), Month 12, Month 24
|
|
General Endocrine Studies
Lasso di tempo: Baseline (0), Month 12, Month 24
|
Serum insulin-like growth factor-1 (IGF-I) will be measured by kit assay (ALPCO Diagnostics, Salem, NH). |
Baseline (0), Month 12, Month 24
|
|
Biomarkers for Bone Formation
Lasso di tempo: Baseline (0), Month 1, Month 3, Month 6, Month 12, Month 18, Month 24
|
Change in levels of bone alkaline phosphatase (MyBiosource, Inc., San Diego, CA) at baseline, month 1, month 3, month 6, month 12, month 18, and month 24. |
Baseline (0), Month 1, Month 3, Month 6, Month 12, Month 18, Month 24
|
|
Biomarkers for Bone Formation
Lasso di tempo: Baseline (0), Month 1, Month 3, Month 6, Month 12, Month 18, Month 24
|
Change in levels of propeptide of type 1 procollagen (P1NP) (MyBiosource, Inc., San Diego, CA) at baseline, month 1, month 3, month 6, month 12, month 18, and month 24. |
Baseline (0), Month 1, Month 3, Month 6, Month 12, Month 18, Month 24
|
Collaboratori e investigatori
Sponsor
Sponsor
Collaboratori
Collaboratori
Investigatori
Investigatori
- Investigatore principale: Christopher Cardozo, MD, James J. Peters Veterans Affairs Medical Center
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Effettivo)
Completamento primario
Completamento dello studio (Effettivo)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Malattie del sistema nervoso centrale
- Malattie del sistema nervoso
- Ferite e lesioni
- Trauma, sistema nervoso
- Malattie del midollo spinale
- Lesioni del midollo spinale
- Aminoacidi, peptidi e proteine
- Proteine
- Preparati farmaceutici
- Anticorpi, monoclonali, umanizzati
- Anticorpi, monoclonali
- Anticorpi
- Immunoglobuline
- Immunoproteine
- Proteine del sangue
- Globuline sieriche
- Globuline
- Soluzioni cristalloidi
- Soluzioni isotoniche
- Soluzioni
- Denosumab
- Soluzione salina
- romosozumab
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- B3415-R
- BAU-19-66 (Altro identificatore: JJP VAMC Local IRB)
- 1600530 (Altro identificatore: JJP VAMC Local IRB)
- 5I01RX003415-06 (Sovvenzione/contratto NIH degli Stati Uniti)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
There is not a plan to make IPD available.
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .